@article{2898c08e0d054a2b998b4774f9f46ad2,
title = "Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern",
abstract = "The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-d/pre-o donor units obtained before March 2021, 20 post-d COVID-19/postvaccination units, and 1 pre-d/pre-o hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], d, and o) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to d or o, respectively.",
author = "Maggie Li and Beck, {Evan J.} and Oliver Laeyendecker and Yolanda Eby and Tobian, {Aaron A.R.} and Patrizio Caturegli and Camille Wouters and Chiklis, {Gregory R.} and William Block and McKie, {Robert O.} and Joyner, {Michael J.} and Wiltshire, {Timothy D.} and Dietz, {Allan B.} and Gniadek, {Thomas J.} and Shapiro, {Arell J.} and Anusha Yarava and Karen Lane and Hanley, {Daniel F.} and Bloch, {Evan M.} and Shmuel Shoham and Cachay, {Edward R.} and Meisenberg, {Barry R.} and Huaman, {Moises A.} and Yuriko Fukuta and Bela Patel and Heath, {Sonya L.} and Levine, {Adam C.} and Paxton, {James H.} and Shweta Anjan and Gerber, {Jonathan M.} and Gebo, {Kelly A.} and Arturo Casadevall and Andrew Pekosz and Sullivan, {David J.}",
note = "Funding Information: This study was funded principally by the US Department of Defense{\textquoteright}s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012); with additional support from Bloomberg Philanthropies; State of Maryland; the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1; NIH NIAID contract N7593021C00045 to the Johns Hopkins Center of Excellence in Influenza Research and Response (JH CEIRR); NIH National Center for Advancing Translational Sciences U24TR001609 and UL1TR003098; Division of Intramural Research NIAID NIH; Mental Wellness Foundation; Moriah Fund; Octapharma; HealthNet-work Foundation; and the Shear Family Foundation. Publisher Copyright: {\textcopyright} 2022 American Society of Hematology. All rights reserved.",
year = "2022",
month = jun,
day = "28",
doi = "10.1182/bloodadvances.2022007410",
language = "English (US)",
volume = "6",
pages = "3678--3683",
journal = "Blood Advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "12",
}